Our clinical trials

Cantargia’s clinical program

Nadunolimab (CAN04)

The IL1RAP-binding antibody CAN04 is Cantargia’s principal candidate and is investigated in multiple clinical trials in combination with chemotherapy or immunotherapy, summarized in the table below. The clinical program for CAN04 initially focused on non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC) but has during 2020 and 2021 been broadened to include additional cancer forms.


A-Eng-Status4A.jpg#asset:3128

Overview of Cantargia’s ongoing clinical studies for CAN04.


CAN10

In the CAN10 project, a new antibody against IL1RAP, customized for treatment of autoimmune and inflammatory diseases, is being developed. The initial focus will be on two severe diseases: myocarditis and systemic sclerosis. The goal is to initiate the first clinical trial for CAN10 in the first half of 2022.